Form 4: Organon & Co. CEO Kevin Ali Reports Stock Transactions
SEC Form 4 Filing
CEO Kevin Ali reports the vesting and conversion of restricted stock units into Organon & Co. common stock, along with the disposition of shares to cover tax obligations.
Summary
- On March 31, 2024, Kevin Ali, CEO of Organon & Co., reported transactions involving Organon common stock and restricted stock units (RSUs).
- A total of 21,471 RSUs vested and were converted into common stock.
- Additionally, 38,973 RSUs vested and were converted into common stock.
- Simultaneously, 11,874 shares were disposed of at a price of $18.80, and 21,553 shares were disposed of at a price of $18.80.
- Following these transactions, Ali directly owns 125,343 shares of Organon common stock and 77,948 restricted stock units.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing detailing stock transactions by the CEO. It doesn't inherently convey positive or negative sentiment about the company's performance.
Industry Context
Form 4 filings are standard disclosures required by the SEC when company insiders, like the CEO, trade their company's stock. These filings provide transparency into insider transactions and are closely watched by investors for signals about management's view of the company's prospects.
Comparison to Industry Standards
- Executive compensation packages often include restricted stock units (RSUs) that vest over time, aligning executive interests with long-term shareholder value.
- The vesting schedules described are typical for RSUs, with vesting occurring over a period of several years.
- The sale of shares to cover tax obligations upon vesting is a common practice among executives receiving equity compensation.
- Comparing Ali's holdings and transactions to those of executives at similar pharmaceutical companies (e.g., Viatris, Teva) would provide further context.
Stakeholder Impact
- The transactions themselves have a minimal direct impact on stakeholders.
- However, transparency in insider transactions is important for maintaining investor confidence.
Key Dates
| Date | Description |
|---|---|
| 03/31/2023 | One-third of the initially granted RSUs vested. |
| 03/31/2024 | Vesting and conversion of RSUs into common stock; disposition of shares for tax obligations. |
| 03/31/2025 | Remaining RSUs from the first grant to vest. |
| 03/31/2025 | Half of the remaining RSUs from the second grant to vest. |
| 03/31/2026 | Final vesting date for the remaining RSUs from the second grant. |
| 04/03/2024 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.